Lazard Asset Management’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$171K Buy
+17,215
New +$152K ﹤0.01% 1719
2026
Q2
– Sell
-17,970
Closed -$115K – 2084
2026
Q1
$115K Sell
17,970
-41,605
-70% -$268K ﹤0.01% 1711
2025
Q4
$354K Sell
59,575
-3,572
-6% -$19K ﹤0.01% 1480
2025
Q3
$335K Buy
+63,147
New +$268K ﹤0.01% 1469
2025
Q2
– Sell
-2,100
Closed -$6K – 2474
2025
Q1
$6K Sell
2,100
-395
-16% -$1.24K ﹤0.01% 2176
2024
Q4
$7K Buy
2,495
+2,005
+409% +$5.83K ﹤0.01% 2118
2024
Q3
$1K Sell
490
-107,413
-100% -$325K ﹤0.01% 2189
2024
Q2
$351K Buy
107,903
+58,437
+118% +$257K ﹤0.01% 1347
2024
Q1
$262K Buy
49,466
+48,520
+5,129% +$261K ﹤0.01% 1217
2023
Q4
$4K Buy
+946
New +$3.13K ﹤0.01% 2132
2021
Q3
– Sell
-6,984
Closed -$64K – 2254
2021
Q2
$64K Buy
+6,984
New +$70.8K ﹤0.01% 1501

Other funds holding PBYI

Lazard Asset Management's PBYI Position: Q3 2026 in Review

Lazard Asset Management opened a new position in Puma Biotechnology (PBYI) in Q3 2026: 17,215 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #1719 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in PBYI as recently as Q1 2026.

Lazard Asset Management first reported a position in PBYI in Q2 2021 and has held it in 11 quarters since. The position peaked at $354K in Q4 2025. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

  • Lazard Asset Management held 17,215 shares of Puma Biotechnology worth $171K as of Q3 2026.
  • Puma Biotechnology was a new Lazard Asset Management position in Q3 2026.
  • Puma Biotechnology made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1719 holding.
  • Lazard Asset Management first reported a position in Puma Biotechnology in Q2 2021 and has held it in 11 quarters since.
  • Lazard Asset Management's Puma Biotechnology position peaked at $354K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.